Ophthalmology

Worldwide, more than 1 billion people live with vision impairment that could have been prevented or has yet to be addressed.1 It is estimated that by 2030, 564,000 Australians will be blind or have low vision.2 Visual impairment can have a devastating impact on those people affected, as well as their caregivers.

Around 90% of all blindness and vision impairment in Australia is preventable or treatable if detected early.3 With new approaches to the diagnosis and treatment of ophthalmic conditions being explored as we speak, this is a global health challenge that we at Roche are committed to and excited to tackle, alongside the low vision community.

Our team is built around the experience of ophthalmologists, ophthalmic surgeons and retinal specialists, who bring real-world insights to their work at Roche every day. We are innovating to improve diagnosis and transform patient experience and outcomes, we do this by understanding the biology of ophthalmic conditions and what this means in practice to people living with vision impairment or loss.

We partner with researchers, clinicians and patient groups from the low vision community to ensure we understand the needs of people experiencing vision impairment or loss. That is so we can try to meet these needs through our approach to innovation, our clinical trial programme and our medicines and technologies in development.

This means examining new insights and analytical sources such as real world data and exploring new technologies such as articial intelligence and machine learning. Importantly, we're developing digital health solutions to help better detect and monitor disease progression and pioneering new therapeutic options to deliver a personalised approach to eye health.